Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by barcodewhizon Nov 17, 2007 7:21pm
224 Views
Post# 13825106

RE: RE: Kedrion Deal...

RE: RE: Kedrion Deal...
Cascade can remove Albumin already though a patented process,  although interestingly it doesnt have much of a yield advantage over the Cohn process.  That's why its particularly relevant  to add the prion removal element as a differentiator for the smaller fractionators to compete on Albumin products with the Baxters of the world AND be able to charge a premium !     This, sin  itself ,  will ultimately give the big boyz cause to start using PLI's prion reduction... or even Cascade at some point.

Of course, Cascades real claim to fame is its ability to garner higher yeilds than COHN on other Plasma components such as IVIG and Factor 8....   In addition to higher yields,  Cascade also is capable of removing other valuable compounds that  the Cohn process cannot remove at all.   

Very smart moves by Kedrion,  at the same time strengthening PLI's prion removal and the Cascade  process' standing in the world Plasma business,  and leading to healthy recurring revenues for Prometic.

Going to be very interesting to see what the Kedrion deal expansion is all about
Bullboard Posts